Literature DB >> 12485296

The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids.

S Fenton, S Kennedy, P Moriarty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12485296     DOI： 10.1034/j.1600-0420.2002.800623_3.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN： 1395-3907


× No keyword cloud information.
  4 in total

1.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

2.  Presence of interferon regulatory factor-1 in aggressive and nonaggressive histological variants of Basal cell carcinoma specimens.

Authors:  Nurten Turhan-Haktanir; F Husniye Dilek; Yavuz Demir; Onder Sahin
Journal:  J Cutan Aesthet Surg       Date:  2010-01

3.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Authors:  Lorenzo Anasagasti-Angulo; Yanelda Garcia-Vega; Silvia Barcelona-Perez; Pedro Lopez-Saura; Iraldo Bello-Rivero
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

4.  Surgery of basal cell carcinoma around the lacrimal canaliculus can be necessary after primary treatment with intralesional interferon alpha 2b.

Authors:  V Huerva; I Mangues
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.